Vor Biopharma Inc.
VOR
Positions held
Your positionsVOR isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Vor Biopharma Inc. operates in the biotechnology sector, focusing on innovative therapies that target specific patient populations, which positions it well for future growth in a competitive market.
- The company's market cap is approximately $1.08 billion, indicating significant investor interest and potential for capital appreciation.
- Vor has a strong buy recommendation with a target mean price of $39.00, suggesting a substantial upside from current levels.
- The company has reported negative net income for several consecutive quarters, with a net income of -62.81 million in Q2 2026 and -219.585 million in Q1 2026, raising concerns about its financial sustainability.
- Vor's trailing P/E ratio is 0.10, indicating that the company is currently unprofitable and may struggle to generate earnings in the near term.
- The stock has a strong sell signal with a score of -16.00, reflecting bearish trends and technical indicators that suggest further declines may be ahead.
Fundamentals
| Market cap | $1.13B | Enterprise value | $668.52M | Trailing P/E | 0.11 | Forward P/E | -5.01 |
| PEG | — | Price / book | -5.20 | Beta | 1.78 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | — | ROA | -21.4% | Debt / equity | — |
| Current ratio | 19.15 | Free cash flow | -$79.50M | Analyst recommendation | strong_buy | Mean target | $39.00 |
| 52w high | $33.50 | 52w low | $6.50 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$62.8M | -$220M | $1.7B | -$813M | -$1.6B | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$47.9M | -$35.2M | -$36.0M | -$28.1M | -$274M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$696M | -$117M | -$118M | -$92.1M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$372M | -$121M | -$126M | -$93.4M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Vor Biopharma (VOR) Could Be 52% Undervalued As Phase 3 gMG Data Draw Focus
2026-10-05 · Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-10-04 · Durable MG Responses From Telitacicept Could Be A Game Changer For Vor Biopharma (VOR)
2026-09-08 · Vor Biopharma Completes Enrollment in Phase 3 Trial of Investigational Drug for Generalized Myasthenia Gravis
2026-09-04 · Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-09-01 · Vor Bio To Participate in Upcoming September Conferences
2026-08-11 · Wedbush Adjusts Price Target on Vor Biopharma to $27 From $18, Keeps Neutral Rating
2026-08-11 · Vor Biopharma Shares Drop After Q2 Results
2026-08-11 · Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Price (daily)
Full chart · RSI · MACD · patterns